Fig. 4From: Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical modelsControlling for general levels of drug sensitivity substantially affects biomarker discovery in the CGP cell lines. a Dot-plot showing the change in P values for the top 25 associations for all sequenced cancer genes across all drugs in CGP. Results are plotted when controlling for GLDS and for an uncorrected approach. Also included are the results when controlling for GLDS estimated from expression data. The triangle is pointing in the direction of the effect (i.e. a triangle pointing up indicates a positive effect). b A similar dot-plot for the 18 novel associations identified in CGP when controlling for GLDSBack to article page